- $2.29bn
- $5.18bn
- $4.25bn
US FDA approves Perrigo's contraceptive pill for over-the-counter use (updated)
Brief: Perrigo Announces U.S. FDA Approval For Opill OTC Daily Oral Contraceptive
US FDA approves Perrigo's over-the-counter contraceptive pill
Perrigo taps Bayer executive as CEO, shares fall
Brief: Perrigo Appoints Patrick Lockwood-Taylor As President And CEO
Brief: Perrigo Announces U.S. FDA Approval For Nicotine Coated Mint Lozenge
Perrigo rises as FDA advisers back OTC use of birth control pill
Brief: U.S. FDA Advisers Vote 17-0 In Favor Of Recommending The Agency Approve Over-The-Counter Use Of Perrigo's Birth Control Pill
U.S. FDA advisers back OTC use of Perrigo's birth control pill (updated)
U.S. FDA advisers back OTC use of Perrigo's birth control pill
Perrigo Company PLC reports results for the quarter ended in March - Earnings Summary
Brief: Perrigo Announces Chief Executive Officer Retirement And Succession Plan
Brief: Perrigo posts Q1 adjusted net income USD 61 million
Brief: Perrigo Reports Q1 Fiscal Year 2023 Financial Results From Continuing Operations
What to Watch in the Day Ahead - Tuesday, May 9
U.S. STOCKS ON THE MOVE-E.W. Scripps Co, LivePerson, Owens & Minor
U.S. STOCKS ON THE MOVE-Icahn Enterprises, Lyft, Western Alliance Bancorp
US FDA staff raises concerns over OTC use of Perrigo's birth control pill (updated)
FDA flags concerns on Perrigo's birth control drug, stock falls